Literature DB >> 2641294

1H NMR studies on protein binding of histidine, tyrosine and phenylalanine in blood plasma.

J K Nicholson1, K P Gartland.   

Abstract

The binding of histidine (His), phenylalanine (Phe) and tyrosine (Tyr) to macromolecules in blood plasma and serum has been investigated by high resolution 1H NMR spectroscopy. In single pulse and spin-echo spectra of quality control bovine serum and normal human plasma, there are no resonances in the chemical shift range to high frequency of delta = 5.3 ppm when measured in the pH* (meter reading, uncorrected for the presence of 2H2O) range 3 to 8.5. On acidification of the plasma to pH* less than 2.5, resonances from His and Phe are observable. In plasma from patients with Wilson's disease, weak signals from His and Tyr are seen in spin-echo spectra at pH* 7.6, but increase in strength on acidification and signals from Phe appear at pH* 1.8. Addition of standard solutions containing Tyr, His and especially Phe and Trp to plasma at neutral pH* results in poor recovery of their expected signal intensity in spin-echo spectra. Addition of 2 M urea to bovine plasma at pH* 4.5 results in the appearance of Phe signals. These data are consistent with Phe and Tyr (and to a lesser extent His) being bound in or to a macromolecular structure at neutral pH from which there is relatively slow exchange with the free solution environment. Experiments with model solutions suggest that serum albumin has a high capacity for binding aromatic amino acids (stabilized by hydrophobic interactions) at neutral pH and this is responsible for the NMR-invisibility of Tyr and Phe in blood plasma.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2641294     DOI: 10.1002/nbm.1940020207

Source DB:  PubMed          Journal:  NMR Biomed        ISSN: 0952-3480            Impact factor:   4.044


  13 in total

1.  Citrate NMR peak irreproducibility in blood samples after reacquisition of spectra.

Authors:  Munsoor A Hanifa; Raluca G Maltesen; Bodil S Rasmussen; Katrine B Buggeskov; Hanne B Ravn; Martin Skott; Søren Nielsen; Jørgen Frøkiær; Troels Ring; Reinhard Wimmer
Journal:  Metabolomics       Date:  2019-12-19       Impact factor: 4.290

Review 2.  Can NMR solve some significant challenges in metabolomics?

Authors:  G A Nagana Gowda; Daniel Raftery
Journal:  J Magn Reson       Date:  2015-08-18       Impact factor: 2.229

3.  Massive glutamine cyclization to pyroglutamic acid in human serum discovered using NMR spectroscopy.

Authors:  G A Nagana Gowda; Yashas N Gowda; Daniel Raftery
Journal:  Anal Chem       Date:  2015-03-17       Impact factor: 6.986

4.  NMR-Guided Mass Spectrometry for Absolute Quantitation of Human Blood Metabolites.

Authors:  G A Nagana Gowda; Danijel Djukovic; Lisa Fan Bettcher; Haiwei Gu; Daniel Raftery
Journal:  Anal Chem       Date:  2018-01-09       Impact factor: 6.986

5.  A Metabolomic Analysis of Cirrhotic Ascites.

Authors:  Diren Beyoğlu; Cedric Simillion; Federico Storni; Andrea De Gottardi; Jeffrey R Idle
Journal:  Molecules       Date:  2022-06-20       Impact factor: 4.927

6.  NMR Spectroscopy-Based Metabolic Profiling of Biospecimens.

Authors:  Arjun Sengupta; Aalim M Weljie
Journal:  Curr Protoc Protein Sci       Date:  2019-12

7.  Evaluation of Fumaric Acid and Maleic Acid as Internal Standards for NMR Analysis of Protein Precipitated Plasma, Serum, and Whole Blood.

Authors:  G A Nagana Gowda; Natalie N Hong; Daniel Raftery
Journal:  Anal Chem       Date:  2021-02-04       Impact factor: 6.986

8.  Quantitating metabolites in protein precipitated serum using NMR spectroscopy.

Authors:  G A Nagana Gowda; Daniel Raftery
Journal:  Anal Chem       Date:  2014-05-14       Impact factor: 6.986

9.  NMR-Based Metabolomics.

Authors:  G A Nagana Gowda; Daniel Raftery
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

10.  Expanding the limits of human blood metabolite quantitation using NMR spectroscopy.

Authors:  G A Nagana Gowda; Yashas N Gowda; Daniel Raftery
Journal:  Anal Chem       Date:  2014-12-08       Impact factor: 6.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.